Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleDronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms.
Author(s)Woodward MR, Harper DG, Stolyar A, Forester BP, Ellison JM.
Journal, Volume, IssueAm J Geriatr Psychiatry 2014;22(4):415-9.
Major outcome(s)A treatment with oral THC was associated with significant decreases in agitation, as well as improvements in sleep duration and appetite.
IndicationAlzheimer's diseaseAbstract
MedicationDelta-9-THC

OBJECTIVE: Behavioral disturbances occur frequently in demented individuals and greatly increase the burden of their care. The efficacy of pharmacotherapeutic treatment options is modest. This study was conducted to explore the efficacy and safety of dronabinol as an adjunctive treatment for agitation and aggressive behavior in severely demented patients. METHODS: Using a retrospective systematic chart review, we studied 40 inpatients from the McLean Hospital Geriatric Neuropsychiatry Inpatient Unit diagnosed with dementia and treated with dronabinol for behavioral or appetite disturbances. A group of geriatric psychiatrists consulted medical records to rate the patients' behaviors prior to initiation of dronabinol treatment and following up to seven days of treatment, using the Pittsburgh Agitation Scale, Clinical Global Impression, and Global Assessment of Functioning. Data on percentage of food consumed at each meal, sleep duration, and adverse events were also collected from medical records.
RESULTS: The addition of dronabinol to patients' treatment regimens was associated with significant decreases in all domains of the Pittsburgh Agitation Scale. There were also significant improvements in Clinical Global Impression scores, sleep duration and percentage of meals consumed during the treatment periods. Twenty-six adverse events were recorded during dronabinol treatment, none of which led to medication discontinuation.
CONCLUSION: This report represents the largest studied cohort of dementia patients treated with dronabinol to date and confirms earlier reports that dronabinol can serve as an adjunctive treatment for neuropsychiatric symptoms in dementia. Further research, including prospective controlled trials, is needed to clarify dronabinol's role in treating noncognitive behavioral symptoms of demented individuals.

Route(s)Oral
Dose(s)
Duration (days)
Participants40 patients diagnosed with dementia
DesignOpen study
Type of publicationMedical journal
Address of author(s)McLean Hospital Geriatric Psychiatry Research Program, Harvard Medical School, Belmont, MA. Electronic address: matthew.woodward@alumni.tufts.edu.
Full textwww.ncbi.nlm.nih.gov/pubmed/23597932

[Back to Overview]  [IACM Homepage]


up